Krystal Biotech, Inc.
KRYS- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001711279
In the last 90 days, Krystal Biotech, Inc. insiders filed 0 open-market purchases and 3 sales; 422 institutions reported holding it in 13F filings for Q2 2026, worth $11.1B in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Krystal Biotech, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 3 filings
- 3 insiders, $26.2M in total
- Insiders trading
- 3
- Net value
- −$26.2M
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Krystal Biotech, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Rossi Dino A | Director | 50,000 | Sep 16, 2026 | 3 |
| Sutherland Everett Rand | Director | – | Sep 16, 2026 | 1 |
| Mazzacco Catherine | Director | – | Sep 16, 2026 | 1 |
| Mason Christopher | Director | – | Sep 16, 2026 | 1 |
| Janney Daniel | Director | 73,293Indirect | Sep 16, 2026 | 3 |
| Gangolli Julian S | Director | 0 | Sep 16, 2026 | 1 |
| Krishnan Suma | President, R&D | 1,302,145 | Sep 4, 2026 | 5 |
| Krishnan Krish S | President and CEO | 1,347,543 | Sep 4, 2026 | 5 |
| Thomas John Charles | EVP, General Counsel | 0 | Jun 26, 2026 | 2 |
| Romano Kathryn | Chief Accounting Officer | 22,366 | Mar 3, 2026 | 2 |
| Orth Andrew C. | Chief Commercial Officer | 100 | Jun 9, 2023 | 0 |
| Marantz Jing L. | Chief Business Officer | – | Jan 31, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jun 5, 2026 (view filing) | Jun 4 | 1 day | Krishnan SumaPresident, R&D | SSale | −25.0K | $308.12 | −$7.70M | −1.8%1.38M after | 11 lots10b5-1 |
| Jun 26, 2026 (view filing) | Jun 25 | 1 day | Thomas John CharlesEVP, General Counsel | SSale | −1.00K | $347.27 | −$347.3K | −100.0%0 after | 10b5-1 |
| Aug 14, 2026 (view filing)6:22 PM ET | Aug 14 | Same day | Rossi Dino ADirector | SSale | −25.0K | $329.12 | −$8.23M | −33.3%50.0K after | 8 lots |
| Sep 4, 2026 (view filing)7:14 PM ET | Sep 4 | Same day | Krishnan Krish SPresident and CEO | SSale | −25.0K | $359.32 | −$8.98M | −1.8%1.35M after | 13 lots10b5-1 |
| Sep 4, 2026 (view filing)7:15 PM ET | Sep 4 | Same day | Krishnan SumaPresident, R&D | SSale | −25.0K | $359.32 | −$8.98M | −1.9%1.30M after | 13 lots10b5-1 |